Daily Archives

One Article

Business Leaders/Businessman

Jim Tananbaum: An Investment Savvy MD with His Own VC Firm

Posted by eastcoop on

Venture capital healthcare firm Foresite Capital added named Molly He, Ph.D. as a venture partner. Dr. He was a senior director at Illumina and before that, she worked on protein reagent development at Pacific Biosciences. In addition, He has a decade’s worth of experience in the pharmaceutical industry where she worked on drugs that targeted cancer. Her substantial experience in genomics and personalized medicine will benefit Foresite Capital as the company continues to furnish growth equity for transformational companies.

Dr. He earned a B.S. in biochemistry from Nankai University then she received her Ph.D. in protein biophysics from the University of California in Los Angeles. CEO Jim Tananbaum said “Dr. He is one of the most respected scientific researchers in the area of next-generation sequencing, and we are thrilled to welcome her to the team.”

Tananbaum decided to institute a merger between his healthcare and his investment education and expertise when he founded Foresite Capital in 2011. His impressive academic career includes earning an M.D. from Harvard Medical School and an MBA from Harvard Business School. Jim of Twitter, Tananbaum co-founded two biopharmaceutical companies, Theravance, Inc. and GelTex Pharmaceuticals. Additionally, Tananbaum’s investment experience is comprised of a partnership at Sierra Ventures and being a founding partner of Prospect Venture Partners. At Sierra Ventures, Tananbaum assisted with originating the firm’s healthcare investment division and learn more about Jim.

Foresite Capital prefers to invest in companies developing disruptive healthcare products and services. As the founder of Foresite Capital, Tananbaum is responsible for the venture capital company’s investment strategy; additionally, he takes on important roles in companies in Foresite Capital’s portfolio. According to Tananbaum, Foresite Capital will invest in companies that will notably affect the quality of the U.S. healthcare system. Tananbaum was included in the Forbes’ Midas List of Top Tech Investors list once again, proving that his decisions as a venture capitalist, he creates exceptional value and more information click here.

More visit: https://www.forbes.com/profile/jim-tananbaum/